Philip C. Buttery

Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial

Stéphane Palfi, Jean Marc Gurruchaga, G. Ralph et al. · The Lancet · 2014 · 432 citations

Gene Therapies, Neurodegenerative Diseases, Dose Escalation +11

Laminin-2/Integrin Interactions Enhance Myelin Membrane Formation by Oligodendrocytes

Philip C. Buttery, Charles ffrench‐Constant · Molecular and Cellular Neuroscience · 1999 · 187 citations

Cell Adhesion, Cell-matrix Interaction, Membrane Biology +7

Long-Term Follow-Up of a Phase I/II Study of ProSavin, a Lentiviral Vector Gene Therapy for Parkinson's Disease

Stéphane Palfi, Jean Marc Gurruchaga, H. Lepetit et al. · Human Gene Therapy Clinical Development · 2018 · 137 citations · Full text

Phase I/ii Study, Dopamine Receptors, Pharmacotherapy +16

Integrins mediate a neuronal survival signal for oligodendrocytes

Emma E. Frost, Philip C. Buttery, Richard Milner et al. · Current Biology · 1999 · 98 citations · Full text

Molecular Neuroscience, Cell-matrix Interaction, Cytoskeleton +8

Expression of dominant-negative and chimeric subunits reveals an essential role for β1 integrin during myelination

João B. Relvas, Anna Setzu, Wia Baron et al. · Current Biology · 2001 · 97 citations · Full text

Cellular Neurobiology, Molecular Physiology, Molecular Neuroscience +13